Review-Recent advances on the action of estrogens and progestogens in normal and pathological human endometrium

Hormone Molecular Biology and Clinical Investigation

Volumn 2, Issue 1, 2010, Pages 155-175

  Pasqualini, Jorge R ^a   Chetrite, Gérard S ^b  

^a Hormones and Cancer Research Unit   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

cancer; endometriosis; endometrium; estrogens; progesterone

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; CATECHOL METHYLTRANSFERASE; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; GLUCURONOSYLTRANSFERASE; HORMONE; HORMONE RECEPTOR; OXYGENASE; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE; SEX HORMONE RECEPTOR; STEROID; STEROID HORMONE; STERYL SULFATASE; SULFOTRANSFERASE; TESTOSTERONE 17BETA DEHYDROGENASE; TIBOLONE; UNCLASSIFIED DRUG;

DRUG EFFICACY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ESTROGEN ACTIVITY; FEMALE; HORMONE ACTION; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; OVARY POLYCYSTIC DISEASE; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEROID METABOLISM; SYSTEMATIC REVIEW (TOPIC);

EID: 84860352945     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.027     Document Type: Article

References (200)

1. Kao LC., Tulac S., Lobo S., Imani B., Yang JP., Germeyer A., Osteen K., Taylor RN., Lessey BA., Giudice LC. Global gene profiling in human endometrium during the window of implantation. Endocrinology 2002;143:2119-38.
2. Chubak J., Tworoger SS., Yasui Y., Ulrich CM., Stanczyk FZ., McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev 2004;13:1296-301.
3. Deligeoroglou E., Michailidis E., Creatsas G. Oral contraceptives and reproductive system cancer. Ann NY Acad Sci 2003;997: 199-208.
4. Anderson GL., Judd HL., Kaunitz AM., Barad DH., Beresford SA., Pettinger M., Liu J., McNeeley SG., Lopez AM. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative Randomized Trial. J Am Med Assoc 2003;290:1739-48.
5. Anderson KE., Anderson E., Mink PJ., Hong CP., Kushi LH., Sellers TA., Lazovich D., Folsom AR. Diabetes and endometrial cancer in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2001;10:611-6.
6. Furberg AS., Thune I. Metabolic abnormalities (hypertension., hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer 2003;104:669-76.
7. Becker S., Dossus L., Kaaks R. Obesity related hyperinsulinae-mia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009;115:86-96.
8. Lucenteforte E., Bosetti C., Talamini R., Montella M., Zucchetto A., Pelucchi C., Franceschi S., Negri E., Levi F., La Vecchia C. Diabetes and endometrial cancer: effect modification by body weight., physical activity and hypertension. Br J Cancer 2007; 97:995-8.
9. Zhang Y., Liu Z., Yu X., Zhang X., Lu S., Chen X., Lu B. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol 2010;117:41-6.
10. Ayabe T., Tsutsumi O., Sakai H., Yoshikawa H., Yano T., Kurimoto F., Taketani Y. Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 1997;44:419-24.
11. Lacey JV Jr., Potischman N., Madigan MP., Berman ML., Mortel R., Twiggs LB., Barrett RJ., Wilbanks GD., Lurain JR., Fillmore CM., Sherman ME., Brinton LA. Insulin-like growth factors., insulin-like growth factor-binding proteins., and endometrial cancer in postmenopausal women: results from a U.S. case-control study. Cancer Epidemiol Biomarkers Prev 2004;13: 607-12.
12. Calle EE., Rodriguez C., Walker-Thurmond K., Thun MJ. Overweight., obesity., and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
13. Trentham-Dietz A., Nichols HB., Hampton JM., Newcomb PA. Weight change and risk of endometrial cancer. Int J Epidemiol 2006;35:151-8.
14. Lindemann K., Vatten LJ., Ellstrom-Engh M., Eskild A. Body mass., diabetes and smoking., and endometrial cancer risk: a follow-up study. Br J Cancer 2008;98:1582-5.
15. Lindemann K., Vatten LJ., Ellstrom-Engh M., Eskild A. Serum lipids and endometrial cancer risk: results from the HUNT-II study. Int J Cancer 2009;124:2938-41.
16. Weiderpass E., Persson I., Adami HO., Magnusson C., Lindgren A., Baron JA. Body size in different periods of life., diabetes mellitus., hypertension., and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000;11:185-92.
17. McTiernan A., Tworoger SS., Ulrich CM., Yasui Y., Irwin ML., Rajan KB., Sorensen B., Rudolph RE., Bowen D., Stanczyk FZ., Potter JD., Schwartz RS. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res 2004;64:2923-8.
18. Colbert LH., Lacey JV Jr., Schairer C., Albert P., Schatzkin A., Albanes D. Physical activity and risk of endometrial cancer in a prospective cohort study (United States). Cancer Causes Control 2003;14:559-67.
19. Friedenreich CM., Cook LS., Magliocco AM., Duggan MA., Courneya KS. Case-control study of lifetime total physical activity and endometrial cancer risk. Cancer Causes Control 2010; DOI: 10.1007/s10552-010-9538-1.
20. Gierach GL., Chang SC., Brinton LA., Lacey JV Jr., Hollenbeck AR., Schatzkin A., Leitzmann MF. Physical activity., sedentary behavior., and endometrial cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2009;124:2139-47.
21. Cust AE., Kaaks R., Friedenreich C., Bonnet F., Laville M., Luka-nova A., Rinaldi S., Dossus L., Slimani N., Lundin E., Tjonneland A., Olsen A., Overvad K., Clavel-Chapelon F., Mesrine S., Joulin V., Linseisen J., Rohrmann S., Pischon T., Boeing H., Trichopoulos D., Trichopoulou A., Benetou V., Palli D., Berrino F., Tumino R., Sacerdote C., Mattiello A., Quiros JR., Mendez MA., Sanchez MJ., Larranaga N., Tormo MJ., Ardanaz E., Bueno-de-Mesquita HB., Peeters PH., van Gils CH., Khaw KT., Bingham S., Allen N., Key T., Jenab M., Riboli E. Plasma adiponectin levels and endome-trial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab 2007;92:255-63.
22. Takemura Y., Osuga Y., Yamauchi T., Kobayashi M., Harada M., Hirata T., Morimoto C., Hirota Y., Yoshino O., Koga K., Yano T., Kadowaki T., Taketani Y. Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology 2006;147:3203-10.
23. Soliman PT., Wu D., Tortolero-Luna G., Schmeler KM., Slomo-vitz BM., Bray MS., Gershenson DM., Lu KH. Association between adiponectin., insulin resistance., and endometrial cancer. Cancer 2006;106:2376-81.
24. Friedenreich CM., Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002;132:3456S-64S.
25. Cust AE., Armstrong BK., Friedenreich CM., Slimani N., Bauman A. Physical activity and endometrial cancer risk: a review of the current evidence., biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes Control 2007;18:243-58.
26. Conroy MB., Sattelmair JR., Cook NR., Manson JE., Buring JE., Lee IM. Physical activity., adiposity., and risk of endometrial cancer. Cancer Causes Control 2009;20:1107-15.
27. Cymbaluk A., Chudecka-Glaz A., Rzepka-Gorska I. Leptin levels in serum depending on body mass index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol 2008;136:74-7.
28. Albrektsen G., Heuch I., Wik E., Salvesen HB. Parity and time interval since childbirth influence survival in endometrial cancer patients. Int J Gynecol Cancer 2009;19:665-9.
29. Dossus L., Allen N., Kaaks R., Bakken K., Lund E., Tjonneland A., Olsen A., Overvad K., Clavel-Chapelon F., Fournier A., Chab-bert-Buffet N., Boeing H., Schutze M., Trichopoulou A., Tricho-poulos D., Lagiou P., Palli D., Krogh V., Tumino R., Vineis P., Mattiello A., Bueno-de-Mesquita HB., Onland-Moret NC., Pee-ters PH., Dumeaux V., Redondo ML., Duell E., Sanchez-Cantalejo E., Arriola L., Chirlaque MD., Ardanaz E., Manjer J., Borgquist S., Lukanova A., Lundin E., Khaw KT., Wareham N., Key T., Chajes V., Rinaldi S., Slimani N., Mouw T., Gallo V., Riboli E. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2009; DOI: 10.1002/ijc.25050.
30. Viswanathan AN., Feskanich D., De Vivo I., Hunter DJ., Barbieri RL., Rosner B., Colditz GA., Hankinson SE. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. Int J Cancer 2005;114:996-1001.
31. Al-Zoughool M., Dossus L., Kaaks R., Clavel-Chapelon F., Tjon-neland A., Olsen A., Overvad K., Boutron-Ruault MC., Gauthier E., Linseisen J., Chang-Claude J., Boeing H., Schulz M., Tricho-poulou A., Chryssa T., Trichopoulos D., Berrino F., Palli D., Mat tiello A., Tumino R., Sacerdote C., Bueno-de-Mesquita HB., Boshuizen HC., Peeters PH., Gram IT., Braaten T., Lund E., Chirlaque MD., Ardanaz E., Agudo A., Larranaga N., Quiros JR., Berglund G., Manjer J., Lundin E., Hallmans G., Khaw KT., Bing-ham S., Allen N., Key T., Jenab M., Cust AE., Rinaldi S., Riboli E. Risk of endometrial cancer in relationship to cigarette smoking: results from the EPIC study. Int J Cancer 2007;121: 2741-7.
32. Polesel J., Serraino D., Zucchetto A., Lucenteforte E., Dal Maso L., Levi F., Negri E., Montella M., Franceschi S., Talamini R., La Vecchia C. Cigarette smoking and endometrial cancer risk: the modifying effect of obesity. Eur J Cancer Prev 2009;18:476-81.
33. Loerbroks A., Schouten LJ., Goldbohm RA., van den Brandt PA. Alcohol consumption., cigarette smoking., and endometrial cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control 2007;18:551-60.
34. Zhou B., Yang L., Sun Q., Cong R., Gu H., Tang N., Zhu H., Wang B. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008;121:501-8.e3.
35. Dai Q., Xu WH., Long JR., Courtney R., Xiang YB., Cai Q., Cheng J., Zheng W., Shu XO. Interaction of soy and 17beta-HSD1 gene polymorphisms in the risk of endometrial cancer. Pharmaco-genet Genomics 2007;17:161-7.
36. Horn-Ross PL., John EM., Canchola AJ., Stewart SL., Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003;95:1158-64.
37. Foyouzi N., Berkkanoglu M., Arici A., Kwintkiewicz J., Izquierdo D., Duleba AJ. Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 2004;82 (Suppl 3):1019-22.
38. Bulun SE. Endometriosis. N Engl J Med 2009;360:268-79.
39. Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 2001;11:339-48.
40. Smuc T., Hevir N., Ribic-Pucelj M., Husen B., Thole H., Rizner TL. Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol 2009;301:59-64.
41. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
42. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun MJ. Cancer statistics., 2008. CA Cancer J Clin 2008;58:71-96.
43. Deligdisch L., Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987;10:237-46.
44. Coulam CB., Annegers JF., Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61: 403-7.
45. Hardiman P., Pillay OC., Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.
46. Gammon MD., Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818-24.
47. Chittenden BG., Fullerton G., Maheshwari A., Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009;19:398-405.
48. Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005;6:103-11.
49. Kong D., Suzuki A., Zou TT., Sakurada A., Kemp LW., Wakatsuki S., Yokoyama T., Yamakawa H., Furukawa T., Sato M., Ohuchi N., Sato S., Yin J., Wang S., Abraham JM., Souza RF., Smolinski KN., Meltzer SJ., Horii A. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
50. Risinger JI., Maxwell GL., Chandramouli GV., Jazaeri A., Apre-likova O., Patterson T., Berchuck A., Barrett JC. Microarray anal ysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003;63: 6-11.
51. Lax SF., Kendall B., Tashiro H., Slebos RJ., Hedrick L. The frequency of p53, K-ras mutations., and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
52. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol 2003;88:263-5.
53. Engelsen IB., Stefansson IM., Beroukhim R., Sellers WR., Meyer-son M., Akslen LA., Salvesen HB. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 2008;32:307-16.
54. Weiderpass E., Adami HO., Baron JA., Magnusson C., Lindgren A., Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.
55. Marsden J., Sturdee D. Cancer issues. Best Pract Res Clin Obstet Gynaecol 2009;23:87-107.
56. Bernstein L., Deapen D., Cerhan JR., Schwartz SM., Liff J., McGann-Maloney E., Perlman JA., Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
57. Cohen I. Endometrial pathologies associated with postmeno-pausal tamoxifen treatment. Gynecol Oncol 2004;94:256-66.
58. Bardin A., Boulle N., Lazennec G., Vignon F., Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004;11:537-51.
59. Weihua Z., Saji S., Makinen S., Cheng G., Jensen EV., Warner M., Gustafsson JA. Estrogen receptor (ER) beta., a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 2000;97: 5936-41.
60. Lindberg MK., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson JA., Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription., supporting a “ying yang” relationship between ERalpha and ERbeta in mice. Mol Endocrinol 2003;17:203-8.
61. Ashton KA., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., Gilbert M., Hamann U., Scott RJ. Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 2009;116: 1053-61.
62. Mote PA., Balleine RL., McGowan EM., Clarke CL. Colocali-zation of progesterone receptors A and B by dual immunofluo-rescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 1999;84:2963-71.
63. Wang H., Critchley HO., Kelly RW., Shen D., Baird DT. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod 1998;4:407-12.
64. Bulun SE., Cheng YH., Yin P., Imir G., Utsunomiya H., Attar E., Innes J., Julie Kim J. Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol 2006;248:94-103.
65. Dassen H., Punyadeera C., Kamps R., Delvoux B., Van Langen-donckt A., Donnez J., Husen B., Thole H., Dunselman G., Groo-thuis P. Estrogen metabolizing enzymes in endometrium and endometriosis. Hum Reprod 2007;22:3148-58.
66. Utsunomiya H., Ito K., Suzuki T., Kitamura T., Kaneko C., Nakata T., Niikura H., Okamura K., Yaegashi N., Sasano H. Steroid sul-fatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 2004;10:5850-6.
67. Bukulmez O., Hardy DB., Carr BR., Word RA., Mendelson CR. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology 2008;149:1190-204.
68. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335: 640-9.
69. Arnett-Mansfield RL., deFazio A., Wain GV., Jaworski RC., Byth K., Mote PA., Clarke CL. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61:4576-82.
70. Hopp TA., Weiss HL., Hilsenbeck SG., Cui Y., Allred DC., Hor-witz KB., Fuqua SA. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004;10:2751-60.
71. Saito S., Ito K., Nagase S., Suzuki T., Akahira J., Okamura K., Yaegashi N., Sasano H. Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Sci 2006;97:1308-14.
72. Berstein LM., Tchernobrovkina AE., Gamajunova VB., Kova-levskij AJ., Vasilyev DA., Chepik OF., Turkevitch EA., Tsyrlina EV., Maximov SJ., Ashrafian LA., Thijssen JH. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 2003;129:245-9.
73. Naitoh K., Honjo H., Yamamoto T., Urabe M., Ogino Y., Yasu-mura T., Nambara T. Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. J Steroid Biochem 1989;33:1049-54.
74. Vermeulen-Meiners C., Poortman J., Haspels AA., Thijssen JH. The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. J Steroid Biochem 1986;24:1073-8.
75. Ito K., Utsunomiya H., Suzuki T., Saitou S., Akahira J., Okamura K., Yaegashi N., Sasano H. 17Beta-hydroxysteroid dehydrogen-ases in human endometrium and its disorders. Mol Cell Endo-crinol 2006;248:136-40.
76. Nelson LR., Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001;45:S116-24.
77. Aghajanova L., Hamilton A., Kwintkiewicz J., Vo KC., Giudice LC. Steroidogenic enzyme and key decidualization marker dys-regulation in endometrial stromal cells from women with versus without endometriosis. Biol Reprod 2009;80:105-14.
78. Matsumoto M., Yamaguchi Y., Seino Y., Hatakeyama A., Takei H., Niikura H., Ito K., Suzuki T., Sasano H., Yaegashi N., Hayashi S. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer 2008;15:451-63.
79. Polow K., Lubbert H., Boquoi E., Kreutzer G., Jeske R., Pollow B. Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma I. Subcellular distribution and variations of specific enzyme activity. Acta Endo-crinol (Copenh) 1975;79:134-45.
80. Tseng L., Gurpide E. Induction of human endometrial estradiol dehydrogenase by progestins. Endocrinology 1975;97:825-33.
81. Benedetto MT., Tabanelli S., Gurpide E. Estrone sulfate sulfatase activity is increased during in vitro decidualization of stromal cells from human endometrium. J Clin Endocrinol Metab 1990;70:342-5.
82. Carlstrom K., Bergqvist A., Ljungberg O. Metabolism of estrone sulfate in endometriotic tissue and in uterine endometrium in proliferative and secretory cycle phase. Fertil Steril 1988;49: 229-33.
83. Buirchell BJ., Hahnel R. Metabolism of estradiol-17beta in human endometrium during the menstrual cycle. J Steroid Bio-chem 1975;6:1489-94.
84. Grosso DS., Way DL. Characterization of cytosolic estrogen sul-fotransferase from RL95-2 endometrial cancer cells. J Clin Endocrinol Metab 1984;59:829-34.
85. Hata H., Holinka CF., Pahuja SL., Hochberg RB., Kuramoto H., Gurpide E. Estradiol metabolism in Ishikawa endometrial cancer cells. J Steroid Biochem 1987;26:699-704.
86. Tseng L., Mazella J., Mann WJ., Chumas J. Estrogen synthesis in normal and malignant human endometrium. J Clin Endo-crinol Metab 1982;55:1029-31.
87. Sasano H., Harada N. Intratumoral aromatase in human breast., endometrial., and ovarian malignancies. Endocr Rev 1998;19: 593-607.
88. Reddy VV., Hanjani P., Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids 1981;37:195-203.
89. Vadlamuri SV., Glover DD., Turner T., Sarkar MA. Regiospe-cific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Cancer Lett 1998;122:143-50.
90. Tsuchiya Y., Nakajima M., Kyo S., Kanaya T., Inoue M., Yokoi T. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004;64:3119-25.
91. Doherty JA., Weiss NS., Freeman RJ., Dightman DA., Thornton PJ., Houck JR., Voigt LF., Rossing MA., Schwartz SM., Chen C. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 2005;14:357-66.
92. Lepine J., Bernard O., Plante M., Tetu B., Pelletier G., Labrie F., Belanger A., Guillemette C. Specificity and regioselectivity of the conjugation of estradiol., estrone., and their catecholestro-gen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometri-um. J Clin Endocrinol Metab 2004;89:5222-32.
93. Tseng L., Gurpide E. Changes in the in vitro metabolism of estradiol by human endometrium during the menstrual cycle. Am J Obstet Gynecol 1972;114:1002-8.
94. Smuc T., Pucelj MR., Sinkovec J., Husen B., Thole H., Lanisnik Rizner T. Expression analysis of the genes involved in estra-diol and progesterone action in human ovarian endometriosis. Gynecol Endocrinol 2007;23:105-11.
95. Ezaki K., Motoyama H., Sasaki H. Immunohistologic localization of estrone sulfatase in uterine endometrium and ade-nomyosis. Obstet Gynecol 2001;98:815-9.
96. Seki M., Hara Y., Sekiya M., Itagaki T., Hirato K., Yanaihara T., Nakayama T. [Changes in steroid enzyme activity in the human endometrium during the menstrual cycle]. Nippon Sanka Fujinka Gakkai Zasshi 1987;39:1571-8.
97. Abulafia O., Lee YC., Wagreich A., Economos K., Serur E., Nacharaju VL. Sulfatase activity in normal and neoplastic endometrium. Gynecol Obstet Invest 2009;67:57-60.
98. Maitoko K., Sasaki H. Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometri-osis in the ovary. Fertil Steril 2004;82:322-6.
99. Fechner S., Husen B., Thole H., Schmidt M., Gashaw I., Kimmig R., Winterhager E., Grummer R. Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissue. Fertil Steril 2007;88:1029-38.
100. Purohit A., Fusi L., Brosens J., Woo LW., Potter BV., Reed MJ. Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. Hum Reprod 2008;23:290-7.
101. Gamage NU., Tsvetanov S., Duggleby RG., McManus ME., Martin JL. The structure of human SULT1A1 crystallized with estradiol. An insight into active site plasticity and substrate inhibition with multi-ring substrates. J Biol Chem 2005;280: 41482-6.
102. Blanchard RL., Freimuth RR., Buck J., Weinshilboum RM., Coughtrie MW. A proposed nomenclature system for the cyto-solic sulfotransferase (SULT) superfamily. Pharmacogenetics 2004;14:199-211.
103. Freimuth RR., Wiepert M., Chute CG., Wieben ED., Weinshil-boum RM. Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes. Phar-macogenomics J 2004;4:54-65.
104. Lindsay J., Wang LL., Li Y., Zhou SF. Structure., function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008;9:99-105.
105. Coughtrie MW. Sulfation through the looking glass-recent advances in sulfotransferase research for the curious. Phar-macogenomics J 2002;2:297-308.
106. Falany JL., Azziz R., Falany CN. Identification and characterization of cytosolic sulfotransferases in normal human endo-metrium. Chem Biol Interact 1998;109:329-39.
107. Falany JL., Falany CN. Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone. Endocrinology 1996;137:1395-401.
108. Kotov A., Falany JL., Wang J., Falany CN. Regulation of estrogen activity by sulfation in human Ishikawa endometrial ade-nocarcinoma cells. J Steroid Biochem Mol Biol 1999;68:137-44.
109. Reich O., Singer C., Hudelist G., Regauer S. Estrogen sulfo-transferase expression in endometrial stromal sarcomas: an immunohistochemical study. Pathol Res Pract 2007;203:85-7.
110. Falany CN., Krasnykh V., Falany JL. Bacterial expression and characterization of a cDNA for human liver estrogen sulfo-transferase. J Steroid Biochem Mol Biol 1995;52:529-39.
111. Hirata H., Hinoda Y., Okayama N., Suehiro Y., Kawamoto K., Kikuno N., Rabban JT., Chen LM., Dahiya R. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008;112:1964-73.
112. Rebbeck TR., Troxel AB., Wang Y., Walker AH., Panossian S., Gallagher S., Shatalova EG., Blanchard R., Bunin G., De-Michele A., Rubin SC., Baumgarten M., Berlin M., Schinnar R., Berlin JA., Strom BL. Estrogen sulfation genes., hormone replacement therapy., and endometrial cancer risk. J Natl Cancer Inst 2006;98:1311-20.
113. Leon L., Bacallao K., Gabler F., Romero C., Valladares L., Vega M. Activities of steroid metabolic enzymes in secretory endo-metria from untreated women with polycystic ovary syndrome. Steroids 2008;73:88-95.
114. Hudelist G., Czerwenka K., Keckstein J., Haas C., Fink-Retter A., Gschwantler-Kaulich D., Kubista E., Singer CF. Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis. Reprod Sci 2007;14:798-805.
115. Bulun SE., Economos K., Miller D., Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994; 79:1831-4.
116. Watanabe K., Sasano H., Harada N., Ozaki M., Niikura H., Sato S., Yajima A. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical., in situ hybridization., and biochemical studies. Am J Pathol 1995;146:491-500.
117. Yamamoto T., Kitawaki J., Urabe M., Honjo H., Tamura T., Noguchi T., Okada H., Sasaki H., Tada A., Terashima Y., Naka-mura J., Yoshihama M. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993;44:463-8.
118. Tseng L. Estrogen synthesis in human endometrial epithelial glands and stromal cells. J Steroid Biochem 1984;20:877-81.
119. Matsuzaki S., Canis M., Pouly JL., Dechelotte PJ., Mage G. Analysis of aromatase and 17beta-hydroxysteroid dehydro-genase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection. Fertil Steril 2006;85:308-13.
120. Kitawaki J., Noguchi T., Amatsu T., Maeda K., Tsukamoto K., Yamamoto T., Fushiki S., Osawa Y., Honjo H. Expression of aromatase cytochrome P450 protein and messenger ribonu-cleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol Reprod 1997;57:514-9.
121. Bulun SE., Mahendroo MS., Simpson ER. Polymerase chain reaction amplification fails to detect aromatase cytochrome P450 transcripts in normal human endometrium or decidua. J Clin Endocrinol Metab 1993;76:1458-63.
122. Segawa T., Shozu M., Murakami K., Kasai T., Shinohara K., Nomura K., Ohno S., Inoue M. Aromatase expression in stro-mal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res 2005;11:2188-94.
123. Jongen VH., Briet JM., de Jong RA., Joppe E., ten Hoor KA., Boezen HM., Evans DB., Hollema H., van der Zee AG., Nijman HW. Aromatase., cyclooxygenase 2, HER-2/neu., and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer 2009;19:670-6.
124. Kitaoka Y., Kitawaki J., Koshiba H., Inoue S., Ishihara H., Tera-moto M., Honjo H. Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters. J Steroid Biochem Mol Biol 2004; 88:183-9.
125. Jongen VH., Thijssen JH., Hollema H., Donker GH., Santema JG., Van der Zee AG., Heineman MJ. Is aromatase cytochrome P450 involved in the pathogenesis of endometrioid endometrial cancer? Int J Gynecol Cancer 2005;15:529-36.
126. Smuc T., Rupreht R., Sinkovec J., Adamski J., Rizner TL. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Mol Cell Endocrinol 2006;248: 114-7.
127. Nagamani M., Hannigan EV., Dillard EA Jr., Van Dinh T. Ovarian steroid secretion in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1986;62: 508-12.
128. Botella-Llusia J., Oriol-Bosch A., Sanchez-Garrido F., Tres-guerres JA. Testosterone and 17 beta-oestradiol secretion of the human ovary. II. Normal postmenopausal women., post-menopausal women with endometrial hyperplasia and post-menopausal women with adenocarcinoma of the endo-metrium. Maturitas 1980;2:7-12.
129. Jongen VH., Hollema H., van der Zee AG., Santema JG., Hei-neman MJ. Ovarian stromal hyperplasia and ovarian vein steroid levels in relation to endometrioid endometrial cancer. BJOG 2003;110:690-5.
130. Jongen VH., Sluijmer AV., Heineman MJ. The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. Maturitas 2002;43:77-85.
131. Berstein L., Zimarina T., Kovalevskij A., Maximov S., Volkov O., Thijssen JH. CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. Neoplasma 2005;52:115-8.
132. Berstein LM., Imyanitov EN., Suspitsin EN., Grigoriev MY., Sokolov EP., Togo A., Hanson KP., Poroshina TE., Vasiljev DA., Kovalevskij AY., Gamajunova VB. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 2001;127:135-8.
133. Setiawan VW., Doherty JA., Shu XO., Akbari MR., Chen C., De Vivo I., Demichele A., Garcia-Closas M., Goodman MT., Hai-man CA., Hankinson SE., Henderson BE., Horn-Ross PL., Lacey JV Jr., Le Marchand L., Levine DA., Liang X., Lissowska J., Lurie G., McGrath M., Narod SA., Rebbeck TR., Ursin G., Weiss NS., Xiang YB., Yang HP., Zheng W., Olson SH. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18:242-7.
134. Bukulmez O., Hardy DB., Carr BR., Auchus RJ., Toloubey-dokhti T., Word RA., Mendelson CR. Androstenedione up-reg-ulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis. J Clin Endocrinol Metab 2008;93:3471-7.
135. Maia H Jr., Casoy J., Valente Filho J. Is aromatase expression in the endometrium the cause of endometriosis and related infertility? Gynecol Endocrinol 2009;25:253-257.
136. Bulun SE., Noble LS., Takayama K., Michael MD., Agarwal V., Fisher C., Zhao Y., Hinshelwood MM., Ito Y., Simpson ER. Endocrine disorders associated with inappropriately high aro-matase expression. J Steroid Biochem Mol Biol 1997;61: 133-9.
137. Kitawaki J., Kusuki I., Koshiba H., Tsukamoto K., Fushiki S., Honjo H. Detection of aromatase cytochrome P-450 in endo-metrial biopsy specimens as a diagnostic test for endometri-osis. Fertil Steril 1999;72:1100-6.
138. Noble LS., Takayama K., Zeitoun KM., Putman JM., Johns DA., Hinshelwood MM., Agarwal VR., Zhao Y., Carr BR., Bulun SE. Prostaglandin E2 stimulates aromatase expression in endo-metriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-6.
139. Velasco I., Rueda J., Acien P. Aromatase expression in endo-metriotic tissues and cell cultures of patients with endometri-osis. Mol Hum Reprod 2006;12:377-81.
140. Noble LS., Simpson ER., Johns A., Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab 1996; 81:174-9.
141. Zeitoun KM., Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9.
142. Zeitoun K., Takayama K., Michael MD., Bulun SE. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol 1999;13:239-53.
143. Attar E., Tokunaga H., Imir G., Yilmaz MB., Redwine D., Put-man M., Gurates B., Attar R., Yaegashi N., Hales DB., Bulun SE. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab 2009;94:623-31.
144. Dube C., Bergeron F., Vaillant MJ., Robert NM., Brousseau C., Tremblay JJ. The nuclear receptors SF1 and LRH1 are expressed in endometrial cancer cells and regulate steroido-genic gene transcription by cooperating with AP-1 factors. Cancer Lett 2009;275:127-38.
145. Salama SA., Kamel MW., Diaz-Arrastia CR., Xu X., Veenstra TD., Salih S., Botting SK., Kumar R. Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. J Clin Endocrinol Metab 2009;94:285-93.
146. Colette S., Lousse JC., Defrere S., Curaba M., Heilier JF., Van Langendonckt A., Mestdagt M., Foidart JM., Loumaye E., Don-nez J. Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod 2009;24:2133-41.
147. Berstein L., Kovalevskij A., Zimarina T., Maximov S., Gershfeld E., Vasilyev D., Baisheva S., Baymakhasheva A., Thijssen JH. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. J Steroid Biochem Mol Biol 2005;95:71-4.
148. Berstein L., Maximov S., Gershfeld E., Meshkova I., Gamaju-nova V., Tsyrlina E., Larionov A., Kovalevskij A., Vasilyev D. Neoadjuvant therapy of endometrial cancer with the aroma-tase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 2002;105:161-5.
149. Ma BB., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W., Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004;14:650-8.
150. Rose PG., Brunetto VL., VanLe L., Bell J., Walker JL., Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2000;78:212-6.
151. Ferrero S., Venturini PL., Ragni N., Camerini G., Remorgida V Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs 2009;69:943-52.
152. Khazaei M., Montaseri A., Casper RF. Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix. Fertil Steril 2009;91:2172-6.
153. Rizner TL., Smuc T., Rupreht R., Sinkovec J., Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006;248:126-35.
154. Smuc T., Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 2009;301:74-82.
155. Utsunomiya H., Suzuki T., Ito K., Moriya T., Konno R., Sato S., Yaegashi N., Okamura K., Sasano H. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydro-genase type 2 in human endometrial carcinoma. Clin Endo-crinol (Oxf) 2003;58:696-703.
156. Pelletier G., Luu-The V., Tetu B., Labrie F. Immunocytoche-mical localization of type 5 17beta-hydroxysteroid dehydro-genase in human reproductive tissues. J Histochem Cytochem 1999;47:731-738.
157. Sasano H., Suzuki T., Takeyama J., Utsunomiya H., Ito K., Ariga N., Moriya T. 17-beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology. Oncology 2000;59(Suppl 1):5-12.
158. Utsunomiya H., Suzuki T., Kaneko C., Takeyama J., Nakamura J., Kimura K., Yoshihama M., Harada N., Ito K., Konno R., Sato S., Okamura K., Sasano H. The analyses of 17beta-hydroxys-teroid dehydrogenase isozymes in human endometrial hyper-plasia and carcinoma. J Clin Endocrinol Metab 2001;86: 3436-43.
159. Zeitoun K., Takayama K., Sasano H., Suzuki T., Moghrabi N., Andersson S., Johns A., Meng L., Putman M., Carr B., Bulun SE. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998;83:4474-80.
160. Delvoux B., Groothuis P., D'Hooghe T., Kyama C., Dunselman G., Romano A. Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. J Clin Endocrinol Metab 2009;94:876-83.
161. Salih SM., Salama SA., Fadl AA., Nagamani M., Al-Hendy A. Expression and cyclic variations of catechol-O-methyl trans-ferase in human endometrial stroma. Fertil Steril 2008;90: 789-97.
162. Salama SA., Kamel MW., Botting S., Salih SM., Borahay MA., Hamed AA., Kilic GS., Saeed M., Williams MY., Diaz-Arrastia CR. Catechol-O-methyltransferase expression and 2-methoxy-estradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS One 2009; 4:e7356.
163. Nishida M., Kasahara K., Kaneko M., Iwasaki H., Hayashi K. [Establishment of a new human endometrial adenocarcinoma cell line., Ishikawa cells., containing estrogen and progesterone receptors]. Nippon Sanka Fujinka Gakkai Zasshi 1985;37: 1103-11.
164. Holinka CF., Hata H., Gravanis A., Kuramoto H., Gurpide E. Effects of estradiol on proliferation of endometrial adenocar-cinoma cells (Ishikawa line). J Steroid Biochem 1986;25:781-6.
165. Holinka CF., Hata H., Kuramoto H., Gurpide E. Responses to estradiol in a human endometrial adenocarcinoma cell line (Ishikawa). J Steroid Biochem 1986;24:85-9.
166. Holinka CF., Hata H., Kuramoto H., Gurpide E. Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line). Cancer Res 1986;46:2771-4.
167. Kleinman D., Karas M., Roberts CT Jr., LeRoith D., Phillip M., Segev Y., Levy J., Sharoni Y. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-bind-ing proteins in endometrial cancer cells by estradiol. Endocrinology 1995;136:2531-7.
168. Hana V., Murphy LJ. Expression of insulin-like growth factors and their binding proteins in the estrogen responsive Ishikawa human endometrial cancer cell line. Endocrinology 1994;135: 2511-6.
169. Gong Y., Ballejo G., Murphy LC., Murphy LJ. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells. Cancer Res 1992;52:1704-9.
170. Chetrite G., Pasqualini JR. Steroid sulphotransferase and 17beta-hydroxysteroid dehydrogenase activities in Ishikawa human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 1997;61:27-34.
171. Nozawa T., Suzuki M., Yabuuchi H., Irokawa M., Tsuji A., Tamai I. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 2005;22:1634-41.
172. Pizzagalli F., Varga Z., Huber RD., Folkers G., Meier PJ., St-Pierre MV. Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab 2003; 88:3902-12.
173. Pollow K., Lubbert H., Pollow B. On the mitochondrial 17beta-hydroxysteroid dehydrogenase from human endometrium and endometrial carcinoma: characterization and intramitochon-drial distribution. J Steroid Biochem 1976;7:45-50.
174. Tseng L., Mazella J., Tseng L. Kinetic studies of human endometrial hydroxysteroid dehydrogenase. J Steroid Biochem 1981;14:437-42.
175. Pollow K., Lubbert H., Jeske R., Pollow B. Studies on 17beta-hydroxysteroid dehydrogenase in human endometrium and endometrial carcinoma. Acta Endocrinol (Copenh) 1975;79: 146-56.
176. Castagnetta LA., Montesanti AM., Granata OM., Oliveri G., Sorci CM., Amodio R., Liquori M., Carruba G. 17 beta-Hydroxysteroid dehydrogenase activity in endometrial cancer cells: different metabolic pathways of estradiol in hormone-responsive and non-responsive intact cells. J Steroid Biochem Mol Biol 1995;55:573-9.
177. Yang S., Fang Z., Gurates B., Tamura M., Miller J., Ferrer K., Bulun SE. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactiva-tion of E2. Mol Endocrinol 2001;15:2093-105.
178. Takahashi-Shiga N., Utsunomiya H., Miki Y., Nagase S., Kobayashi R., Matsumoto M., Niikura H., Ito K., Yaegashi N. Local biosynthesis of estrogen in human endometrial carcinoma through tumor-stromal cell interactions. Clin Cancer Res 2009;15:6028-34.
179. Salih SM., Salama SA., Jamaluddin M., Fadl AA., Blok LJ., Burger CW., Nagamani M., Al-Hendy A. Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells. Reprod Sci 2008;15:210-20.
180. Vivacqua A., Bonofiglio D., Recchia AG., Musti AM., Picard D., Ando S., Maggiolini M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006;20:631-46.
181. Lin BC., Suzawa M., Blind RD., Tobias SC., Bulun SE., Scanlan TS., Ingraham HA. Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 2009;69:5415-23.
182. He YY., Cai B., Yang YX., Liu XL., Wan XP. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation., invasion potential., and interleukin-6 secretion via the MEK/ERK mito-gen-activated protein kinase pathway. Cancer Sci 2009;100: 1051-61.
183. Cong L., Gasser J., Zhao J., Yang B., Li F., Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells., HEC-1-A and RL95 2. Endocr Relat Cancer 2007;14:713-20.
184. Wiegratz I., Sanger N., Kuhl H. Formation of 7 alpha-methyl-ethinyl estradiol during treatment with tibolone. Menopause 2002;9:293-5.
185. Kuhl H., Wiegratz I. In vivo conversion of TIB to MEE not an artifact generated by heat. Menopause 2007;14:331-4; author reply 34-5.
186. Davis SR., Simpson ER., Kuhl H., Wiegratz I. Tibolone was associated with an increase in 7 alpha-methyl-ethinylestradiol. Menopause 2003;10:105-6; author reply 6-7.
187. Kloosterboer HJ. Tibolone is not aromatized in postmenopau-sal women. Climacteric 2008;11:175; author reply 75-6.
188. de Gooyer ME., Oppers-Tiemissen HM., Leysen D., Verheul HA., Kloosterboer HJ. Tibolone is not converted by human aromatase to 7alpha-methyl-17alpha-ethynylestradiol (7alpha-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS. Steroids 2003;68:235-43.
189. Droge MJ., Oostebring F., Oosting E., Verheul HA., Klooster-boer HJ. 7alpha-Methyl-ethinyl estradiol is not a metabolite of tibolone but a chemical stress artifact. Menopause 2007; 14:474-80.
190. Sadarangani A., Salgado AM., Kato S., Pinto M., Carvajal A., Monso C., Owen GI., Vigil P. In vivo and in vitro estrogenic and progestagenic actions of Tibolone. Biol Res 2005;38: 245-58.
191. Beral V., Bull D., Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
192. Rossouw JE., Anderson GL., Prentice RL., LaCroix AZ., Koo-perberg C., Stefanick ML., Jackson RD., Beresford SA., Howard BV., Johnson KC., Kotchen JM., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33.
193. Archer DF., Hendrix S., Ferenczy A., Felix J., Gallagher JC., Rymer J., Skouby SO., den Hollander W., Stathopoulos V., Hel-mond FA. Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007; 88:866-78.
194. Ettinger B., Kenemans P., Johnson SR., Mol-Arts M., Van Os S., Seifert W., Verweij PJ., Cummings SR. Endometrial effects of tibolone in elderly., osteoporotic women. Obstet Gynecol 2008;112:653-9.
195. Archer DF., Hendrix S., Gallagher JC., Rymer J., Skouby S., Ferenczy A., den Hollander W., Stathopoulos V., Helmond FA. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-8.
196. Kenemans P., Bundred NJ., Foidart JM., Kubista E., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Yip CH., Egberts J., Mol-Arts M., Mulder R., van Os S., Beckmann MW. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind., randomised., non-inferiority trial. Lancet Oncol 2009;10:135-46.
197. Kenemans P., Kubista E., Foidart JM., Yip CH., von Schoultz B., Sismondi P., Vassilopoulou-Sellin R., Beckmann MW., Bun-dred NJ., Egberts J., van Os S., Planellas J. Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients-design and baseline data 'LIBERATE' trial. Breast 2007;16(Suppl 2):S182-9.
198. Cummings SR., Ettinger B., Delmas PD., Kenemans P., Statho-poulos V., Verweij P., Mol-Arts M., Kloosterboer L., Mosca L., Christiansen C., Bilezikian J., Kerzberg EM., Johnson S., Zan-chetta J., Grobbee DE., Seifert W., Eastell R. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708.
199. Kubista E., Planellas Gomez JV., Dowsett M., Foidart JM., Poh-lodek K., Serreyn R., Nechushkin M., Manikhas AG., Semigla-zov VF., Hageluken CC., Singer CF. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER + patients: results from STEM trial. Clin Cancer Res 2007; 13:4185-90.
200. Falany JL., Falany CN. Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone. Steroids 2006; 71:880-5.